Nachrichten |
| Datum / Uhrzeit |
Titel |
Bewertung |
| 24.08.25 07:03:33 |
Redcare Pharmacy NV (ETR:RDC): Are Analysts Optimistic? |
 |
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Redcare Pharmacy NV (ETR:RDC) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Redcare Pharmacy NV operates the online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, the Czech Republic, and France. With the latest financial year loss of €45m and a trailing-twelve-month loss of €35m, the €1.9b market-cap company alleviated its loss by moving closer towards its target of breakeven. The most pressing concern for investors is Redcare Pharmacy's path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts’ expectations for the company.
Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.
According to the 9 industry analysts covering Redcare Pharmacy, the consensus is that breakeven is near. They expect the company to post a final loss in 2025, before turning a profit of €13m in 2026. So, the company is predicted to breakeven just over a year from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 54% is expected, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.XTRA:RDC Earnings Per Share Growth August 24th 2025
Underlying developments driving Redcare Pharmacy's growth isn’t the focus of this broad overview, though, bear in mind that by and large a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.
View our latest analysis for Redcare Pharmacy
Before we wrap up, there’s one issue worth mentioning. Redcare Pharmacy currently has a relatively high level of debt. Typically, debt shouldn’t exceed 40% of your equity, which in Redcare Pharmacy's case is 73%. Note that a higher debt obligation increases the risk in investing in the loss-making company.
Next Steps:
This article is not intended to be a comprehensive analysis on Redcare Pharmacy, so if you are interested in understanding the company at a deeper level, take a look at Redcare Pharmacy's company page on Simply Wall St. We've also put together a list of important aspects you should further examine:
Valuation: What is Redcare Pharmacy worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Redcare Pharmacy is currently mispriced by the market. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Redcare Pharmacy’s board and the CEO’s background. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments |
| 03.08.25 08:00:49 |
Redcare Pharmacy Second Quarter 2025 Ergebnis: EPS: €0.46 (vs €0.21 Verlust in 2Q 2024) |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Redcare Pharmacy (ETR:RDC) Ergebnisse des zweiten Quartals 2025
Wichtigste Finanzergebnisse
Umsatz: 709,2 Mio. € (bis 27% ab 2Q 2024). Nettoeinkommen: 9,35 Mio. € (bis zu 4,27 Mio. € Verlust im 2Q 2024). Gewinnspanne: 1,3% (aufgrund des Nettoverlusts im 2Q 2024). Der Umzug zur Rentabilität wurde durch höhere Einnahmen getrieben. EPS: €0,46 (bis zu € 0,21 Verlust im 2Q 2024).
Diese Technologie könnte Computer ersetzen: Entdecken Sie die 20 Aktien arbeiten, um Quanten-Computing Realität zu machen. XTRA:RDC Ergebnis und Umsatz Geschichte 3. August 2025
Alle in der obigen Abbildung dargestellten Zahlen sind für die Dauer von 12 Monaten (TTM)
Redcare Pharmacy erzielt Einblicke
Im Vorfeld wird erwartet, dass die Umsatzerlöse in den nächsten 3 Jahren im Durchschnitt um 16 % wachsen, verglichen mit einer 4,7 %-Wachstumsprognose für die Konsumgüterindustrie in Europa.
Leistung des Marktes in Deutschland.
Die Aktien des Unternehmens sind vor einer Woche um 14 % zurückgegangen.
Analyse der Bilanz
Während das Ergebnis wichtig ist, ist ein weiterer Bereich, der die Bilanz berücksichtigt. Wir haben eine Analyse durchgeführt und Sie können die Bilanz von Redcare Pharmacy sehen.
Haben Sie Feedback zu diesem Artikel? Über den Inhalt? Kontaktieren Sie uns direkt. Alternativ, E-Mail Editorial-team (at) einfachwallst.com.
Dieser Artikel von Simply Wall St ist allgemein in der Natur. Wir liefern Kommentare basierend auf historischen Daten und Analystenprognosen nur unter Verwendung einer unvoreingenommenen Methodik und unsere Artikel sind nicht als Finanzberatung gedacht. Es stellt keine Empfehlung dar, Aktien zu kaufen oder zu verkaufen, und berücksichtigt nicht Ihre Ziele oder Ihre finanzielle Situation. Wir wollen Ihnen langfristig fokussierte Analyse durch grundlegende Daten bringen. Beachten Sie, dass unsere Analyse möglicherweise nicht in den neuesten preisempfindlichen Unternehmensankündigungen oder qualitativen Material ausschlaggebend ist. Einfach Wand St hat keine Position in den genannten Beständen.
Kommentare anzeigen |
| 17.07.25 04:34:49 |
While institutions invested in Redcare Pharmacy NV (ETR:RDC) benefited from last week's 4.8% gain, individual investors stood to gain the most |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Key Insights
The considerable ownership by individual investors in Redcare Pharmacy indicates that they collectively have a greater say in management and business strategy A total of 13 investors have a majority stake in the company with 51% ownership Insiders have bought recently
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.
To get a sense of who is truly in control of Redcare Pharmacy NV (ETR:RDC), it is important to understand the ownership structure of the business. With 40% stake, individual investors possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).
While individual investors were the group that reaped the most benefits after last week’s 4.8% price gain, institutions also received a 30% cut.
Let's take a closer look to see what the different types of shareholders can tell us about Redcare Pharmacy.
View our latest analysis for Redcare Pharmacy XTRA:RDC Ownership Breakdown July 17th 2025
What Does The Institutional Ownership Tell Us About Redcare Pharmacy?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
As you can see, institutional investors have a fair amount of stake in Redcare Pharmacy. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Redcare Pharmacy, (below). Of course, keep in mind that there are other factors to consider, too.XTRA:RDC Earnings and Revenue Growth July 17th 2025
We note that hedge funds don't have a meaningful investment in Redcare Pharmacy. Galenica AG is currently the company's largest shareholder with 10.0% of shares outstanding. For context, the second largest shareholder holds about 7.2% of the shares outstanding, followed by an ownership of 4.7% by the third-largest shareholder.
Looking at the shareholder registry, we can see that 51% of the ownership is controlled by the top 13 shareholders, meaning that no single shareholder has a majority interest in the ownership.
Story Continues
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
Insider Ownership Of Redcare Pharmacy
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
Our information suggests that insiders maintain a significant holding in Redcare Pharmacy NV. It is very interesting to see that insiders have a meaningful €266m stake in this €2.0b business. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.
General Public Ownership
With a 40% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Redcare Pharmacy. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Private Company Ownership
We can see that Private Companies own 7.2%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
Public Company Ownership
It appears to us that public companies own 10.0% of Redcare Pharmacy. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand Redcare Pharmacy better, we need to consider many other factors.
I like to dive deeper into how a company has performed in the past. You can find historic revenue and earnings in this detailed graph.
Ultimately the future is most important. You can access this freereport on analyst forecasts for the company.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments |
| 28.03.25 10:05:27 |
European Growth Stocks Insiders Are Betting On |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
As European markets show signs of recovery, with the STOXX Europe 600 Index snapping a two-week losing streak, investors are keeping a close watch on growth stocks that insiders are heavily investing in. In an environment where government spending hopes and trade tensions shape economic forecasts, companies with high insider ownership can signal confidence from those closest to their operations.
Top 10 Growth Companies With High Insider Ownership In Europe
Name Insider Ownership Earnings Growth Elicera Therapeutics (OM:ELIC) 27.8% 97.2% Pharma Mar (BME:PHM) 11.8% 40.8% Vow (OB:VOW) 13.1% 111.2% Bergen Carbon Solutions (OB:BCS) 12% 50.8% Truecaller (OM:TRUE B) 29.7% 24.7% Elliptic Laboratories (OB:ELABS) 22.6% 88.2% CD Projekt (WSE:CDR) 29.7% 36.8% Ortoma (OM:ORT B) 27.7% 68.6% Nordic Halibut (OB:NOHAL) 29.8% 56.3% Circus (XTRA:CA1) 26% 51.4%
Click here to see the full list of 238 stocks from our Fast Growing European Companies With High Insider Ownership screener.
Let's review some notable picks from our screened stocks.
Stadler Rail
Simply Wall St Growth Rating: ★★★★★☆
Overview: Stadler Rail AG, with a market cap of CHF2.15 billion, is involved in the manufacture and sale of trains across Switzerland, Germany, Austria, Western and Eastern Europe, the Americas, CIS countries, and internationally through its subsidiaries.
Operations: Stadler Rail's revenue is primarily derived from its Rolling Stock segment at CHF2.74 billion, followed by Service & Components at CHF866.43 million, and Signalling at CHF109.11 million.
Insider Ownership: 14.5%
Earnings Growth Forecast: 46.1% p.a.
Stadler Rail, with significant insider ownership, faces challenges as recent earnings show a decline in net income to CHF 38.42 million from CHF 124.32 million year-on-year, and profit margins have decreased to 1.2%. Despite this, the company is poised for substantial growth, with earnings expected to rise significantly at an annual rate of 46.1%, outpacing the Swiss market's average growth forecast of 11.1%.
Get an in-depth perspective on Stadler Rail's performance by reading our analyst estimates report here. Our comprehensive valuation report raises the possibility that Stadler Rail is priced higher than what may be justified by its financials.SWX:SRAIL Earnings and Revenue Growth as at Mar 2025
Fielmann Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Fielmann Group AG operates in the optical and hearing aid sectors across Germany, Switzerland, Austria, and internationally with a market cap of €3.62 billion.
Operations: The company generates revenue of €2.16 billion from its medical-optical supplies segment.
Insider Ownership: 17.9%
Story Continues
Earnings Growth Forecast: 20.6% p.a.
Fielmann Group, with substantial insider ownership, is positioned for growth as its earnings are forecast to increase significantly by 20.6% annually over the next three years, surpassing the German market's average. Despite trading at a discount of 45.3% below fair value estimates and an unstable dividend history, analysts agree on a potential stock price rise of 29.4%. Recent management changes include Peter Lothes joining the board as a member, effective March 2025.
Click here and access our complete growth analysis report to understand the dynamics of Fielmann Group. According our valuation report, there's an indication that Fielmann Group's share price might be on the cheaper side.XTRA:FIE Earnings and Revenue Growth as at Mar 2025
Redcare Pharmacy
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Redcare Pharmacy NV operates as an online pharmacy across several European countries, including the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France with a market cap of €2.53 billion.
Operations: The company generates revenue through its DACH segment with earnings of €1.93 billion and its International segment with earnings of €436.50 million.
Insider Ownership: 11.7%
Earnings Growth Forecast: 47.8% p.a.
Redcare Pharmacy shows promising growth potential, with insiders actively buying shares recently. The company trades at a substantial discount of 58.6% below its estimated fair value, and revenue is expected to grow by 15.9% annually, outpacing the German market's average growth rate. Despite current losses, Redcare anticipates becoming profitable within three years and projects over 25% sales growth for 2025. Recent legal victories support its business model of offering bonuses on prescription orders.
Unlock comprehensive insights into our analysis of Redcare Pharmacy stock in this growth report. The valuation report we've compiled suggests that Redcare Pharmacy's current price could be inflated.XTRA:RDC Earnings and Revenue Growth as at Mar 2025
Taking Advantage
Get an in-depth perspective on all 238 Fast Growing European Companies With High Insider Ownership by using our screener here. Curious About Other Options? We've found 20 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include SWX:SRAIL XTRA:FIE and XTRA:RDC.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments |
| 14.03.25 05:45:09 |
Analysts Are Updating Their Redcare Pharmacy NV (ETR:RDC) Estimates After Its Yearly Results |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Investors in Redcare Pharmacy NV (ETR:RDC) had a good week, as its shares rose 2.9% to close at €127 following the release of its yearly results. Revenues came in at €2.4b, in line with expectations, while statutory losses per share were substantially higher than expected, at €2.27 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Redcare Pharmacy after the latest results.
See our latest analysis for Redcare Pharmacy XTRA:RDC Earnings and Revenue Growth March 14th 2025
Taking into account the latest results, the current consensus from Redcare Pharmacy's twelve analysts is for revenues of €2.96b in 2025. This would reflect a substantial 25% increase on its revenue over the past 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 60% to €0.90. Before this latest report, the consensus had been expecting revenues of €2.96b and €0.83 per share in losses. So it's pretty clear consensus is mixed on Redcare Pharmacy after the new consensus numbers; while the analysts held their revenue numbers steady, they also administered a moderate increase in per-share loss expectations.
The consensus price target held steady at €165, seemingly implying that the higher forecast losses are not expected to have a long term impact on the company's valuation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Redcare Pharmacy at €214 per share, while the most bearish prices it at €93.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The period to the end of 2025 brings more of the same, according to the analysts, with revenue forecast to display 25% growth on an annualised basis. That is in line with its 23% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 4.9% annually. So it's pretty clear that Redcare Pharmacy is forecast to grow substantially faster than its industry.
Story Continues
The Bottom Line
The most important thing to take away is that the analysts increased their loss per share estimates for next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at €165, with the latest estimates not enough to have an impact on their price targets.
With that in mind, we wouldn't be too quick to come to a conclusion on Redcare Pharmacy. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Redcare Pharmacy going out to 2027, and you can see them free on our platform here..
It might also be worth considering whether Redcare Pharmacy's debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments |
| 13.03.25 05:08:03 |
European Value Stocks Trading Below Estimated Worth In March 2025 |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
As European markets navigate a landscape marked by U.S. trade policy uncertainties and recent ECB rate cuts, investor sentiment has been mixed, with the STOXX Europe 600 Index snapping a ten-week streak of gains. Amid these conditions, identifying stocks trading below their estimated worth can offer potential opportunities for investors seeking value in an otherwise cautious market environment.
Top 10 Undervalued Stocks Based On Cash Flows In Europe
Name Current Price Fair Value (Est) Discount (Est) Vimi Fasteners (BIT:VIM) €0.965 €1.91 49.4% Airbus (ENXTPA:AIR) €164.10 €321.27 48.9% Wienerberger (WBAG:WIE) €34.68 €69.35 50% Comet Holding (SWX:COTN) CHF234.50 CHF462.48 49.3% Theon International (ENXTAM:THEON) €19.00 €37.22 49% Net Insight (OM:NETI B) SEK4.81 SEK9.62 50% JOST Werke (XTRA:JST) €50.50 €98.69 48.8% Vestas Wind Systems (CPSE:VWS) DKK103.35 DKK201.48 48.7% Xplora Technologies (OB:XPLRA) NOK27.00 NOK53.73 49.7% Neosperience (BIT:NSP) €0.538 €1.06 49.2%
Click here to see the full list of 200 stocks from our Undervalued European Stocks Based On Cash Flows screener.
Let's take a closer look at a couple of our picks from the screened companies.
Believe
Overview: Believe S.A. is a company that offers digital music services to independent labels and local artists across various regions including France, Germany, the rest of Europe, the Americas, Asia, Oceania, and the Pacific with a market cap of €1.51 billion.
Operations: The company's revenue is primarily generated from its Premium Solutions segment, which accounts for €877.53 million, and its Automated Solutions segment, contributing €61.50 million.
Estimated Discount To Fair Value: 20.5%
Believe's stock is trading at €14.98, which is 20.5% below its estimated fair value of €18.83, highlighting potential undervaluation based on cash flows. Despite a slower forecasted revenue growth of 13% per year compared to the broader market, earnings are expected to grow significantly at 56.95% annually and the company is projected to become profitable within three years, suggesting robust future performance relative to its current valuation in Europe.
Insights from our recent growth report point to a promising forecast for Believe's business outlook. Click here and access our complete balance sheet health report to understand the dynamics of Believe.ENXTPA:BLV Discounted Cash Flow as at Mar 2025
IMMOFINANZ
Overview: IMMOFINANZ AG is a real estate company that acquires, develops, owns, rents, and manages properties mainly in Austria, Germany, Poland, the Czech Republic, Hungary, Romania, Slovakia and the Adriatic region with a market cap of €2.21 billion.
Story Continues
Operations: The company's revenue primarily comes from its Office segment, generating €237.95 million, and its Retail segment, contributing €298.13 million.
Estimated Discount To Fair Value: 19.1%
IMMOFINANZ, now CPI Europe AG, trades at €16.02, below its estimated fair value of €19.8, reflecting potential undervaluation based on cash flows. Despite slower revenue growth forecasts of 2.5% annually compared to the Austrian market's 1.4%, earnings are projected to grow significantly at 70.61% per year with profitability expected within three years. However, debt coverage by operating cash flow remains a concern amidst recent board changes following the S IMMO AG squeeze-out.
The analysis detailed in our IMMOFINANZ growth report hints at robust future financial performance. Dive into the specifics of IMMOFINANZ here with our thorough financial health report.WBAG:IIA Discounted Cash Flow as at Mar 2025
Redcare Pharmacy
Overview: Redcare Pharmacy NV operates as an online pharmacy across several European countries, including the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France with a market cap of €2.66 billion.
Operations: The company generates revenue through its DACH segment, contributing €1.93 billion, and its International segment, which brings in €436.50 million.
Estimated Discount To Fair Value: 45.6%
Redcare Pharmacy trades at €130.7, significantly below its estimated fair value of €240.44, suggesting undervaluation based on cash flows. Despite reporting a net loss of €45.46 million for 2024, the company is expected to achieve profitability within three years with earnings growth projected at 51.07% annually and revenue growth outpacing the German market at 15.7% per year. Recent legal victories support potential future revenue enhancements through prescription order bonuses.
In light of our recent growth report, it seems possible that Redcare Pharmacy's financial performance will exceed current levels. Delve into the full analysis health report here for a deeper understanding of Redcare Pharmacy.XTRA:RDC Discounted Cash Flow as at Mar 2025
Taking Advantage
Click here to access our complete index of 200 Undervalued European Stocks Based On Cash Flows. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Searching for a Fresh Perspective?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ENXTPA:BLV WBAG:IIA and XTRA:RDC.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments |
| 12.03.25 04:40:58 |
Redcare Pharmacy Full Year 2024 Earnings: EPS Misses Expectations |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Redcare Pharmacy (ETR:RDC) Full Year 2024 Results
Key Financial Results
Revenue: €2.37b (up 32% from FY 2023). Net loss: €45.5m (loss widened by 278% from FY 2023). €2.27 loss per share (further deteriorated from €0.63 loss in FY 2023).XTRA:RDC Earnings and Revenue Growth March 12th 2025
All figures shown in the chart above are for the trailing 12 month (TTM) period
Redcare Pharmacy EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 16%.
Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe.
Performance of the market in Germany.
The company's shares are up 15% from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. See our latest analysis on Redcare Pharmacy's balance sheet health.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments |
| 27.02.25 05:05:44 |
European Growth Companies With High Insider Ownership |
 |
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Amidst cautious optimism in Europe, the pan-European STOXX Europe 600 Index has shown slight gains as investors navigate U.S. trade policy developments and efforts to resolve the Russia-Ukraine conflict. In this environment, growth companies with high insider ownership can present intriguing opportunities, as such ownership often signals confidence from those closest to the business and may align management's interests with shareholders'.
Top 10 Growth Companies With High Insider Ownership In Europe
Name Insider Ownership Earnings Growth TF Bank (OM:TFBANK) 15.6% 20% CD Projekt (WSE:CDR) 29.7% 39.4% Bergen Carbon Solutions (OB:BCS) 12% 50.8% Truecaller (OM:TRUE B) 29.7% 24.8% XTPL (WSE:XTP) 27.9% 118% BioArctic (OM:BIOA B) 33.8% 38.5% Pharma Mar (BME:PHM) 11.9% 45.4% Smart Eye (OM:SEYE) 13.7% 127.8% Elliptic Laboratories (OB:ELABS) 22.6% 121.1% MedinCell (ENXTPA:MEDCL) 13.9% 114.3%
Click here to see the full list of 212 stocks from our Fast Growing European Companies With High Insider Ownership screener.
Let's explore several standout options from the results in the screener.
CVC Capital Partners
Simply Wall St Growth Rating: ★★★★★☆
Overview: CVC Capital Partners plc is a private equity and venture capital firm that focuses on middle market secondaries, infrastructure and credit, management buyouts, leveraged buyouts, growth equity, mature investments, recapitalizations, strip sales, and spinouts with a market cap of €24.61 billion.
Operations: CVC Capital Partners plc generates revenue through its focus on private equity and venture capital activities, specializing in areas such as middle market secondaries, infrastructure and credit investments, management and leveraged buyouts, growth equity, mature investments, recapitalizations, strip sales, and spinouts.
Insider Ownership: 20.2%
CVC Capital Partners is experiencing significant earnings growth, forecasted at 27.44% annually, outpacing the Dutch market's 12.6%. Despite a high debt level, it trades at an attractive valuation, 11.6% below its estimated fair value. Recent M&A activity includes potential acquisitions and divestments in the healthcare and telecommunications sectors. Insider ownership remains strong with no substantial insider trading reported recently, supporting confidence in its strategic direction amidst ongoing market maneuvers.
Click here to discover the nuances of CVC Capital Partners with our detailed analytical future growth report. Our valuation report here indicates CVC Capital Partners may be overvalued.ENXTAM:CVC Ownership Breakdown as at Feb 2025
NIBE Industrier
Simply Wall St Growth Rating: ★★★★☆☆
Overview: NIBE Industrier AB (publ) is a company that, along with its subsidiaries, develops, manufactures, markets, and sells energy-efficient solutions for indoor climate comfort and intelligent heating and control across Nordic countries, Europe, North America, and internationally; it has a market cap of approximately SEK83.16 billion.
Story Continues
Operations: The company's revenue segments consist of SEK3.86 billion from Stoves, SEK11.09 billion from Element, and SEK26.04 billion from Climate Solutions.
Insider Ownership: 20.2%
NIBE Industrier demonstrates robust earnings growth potential, forecasted at 27.6% annually, surpassing the Swedish market's 9.6%. Despite a recent dip in annual sales to SEK 40.52 billion and reduced profit margins from 10.3% to 2.9%, the company maintains strong insider ownership with no significant insider trading activity reported recently. However, interest payments are not well covered by earnings, and return on equity is expected to remain low at 10.7%.
Delve into the full analysis future growth report here for a deeper understanding of NIBE Industrier. Upon reviewing our latest valuation report, NIBE Industrier's share price might be too optimistic.OM:NIBE B Ownership Breakdown as at Feb 2025
Redcare Pharmacy
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Redcare Pharmacy NV operates as an online pharmacy across the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France with a market cap of €2.51 billion.
Operations: The company generates revenue from two main segments: DACH, contributing €1.82 billion, and International, contributing €410.50 million.
Insider Ownership: 11.7%
Redcare Pharmacy's revenue is forecast to grow at 16.3% annually, outpacing the German market's 5.8%, though slower than the ideal 20%. Earnings are expected to rise by 58.28% yearly, with profitability anticipated within three years, surpassing average market growth. Insider confidence is evident through substantial share purchases over the past three months and no significant sales. Trading significantly below estimated fair value enhances its appeal despite a low future return on equity forecast of 17%.
Dive into the specifics of Redcare Pharmacy here with our thorough growth forecast report. Our valuation report unveils the possibility Redcare Pharmacy's shares may be trading at a premium.XTRA:RDC Ownership Breakdown as at Feb 2025
Turning Ideas Into Actions
Delve into our full catalog of 212 Fast Growing European Companies With High Insider Ownership here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Want To Explore Some Alternatives?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include ENXTAM:CVC OM:NIBE B and XTRA:RDC.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments |
| 16.02.25 06:00:19 |
When Will Redcare Pharmacy NV (ETR:RDC) Become Profitable? |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
With the business potentially at an important milestone, we thought we'd take a closer look at Redcare Pharmacy NV's (ETR:RDC) future prospects. Redcare Pharmacy NV operates in online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. The €2.3b market-cap company posted a loss in its most recent financial year of €12m and a latest trailing-twelve-month loss of €25m leading to an even wider gap between loss and breakeven. As path to profitability is the topic on Redcare Pharmacy's investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.
See our latest analysis for Redcare Pharmacy
According to the 12 industry analysts covering Redcare Pharmacy, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2025, before generating positive profits of €44m in 2026. So, the company is predicted to breakeven just over a year from now. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 58% year-on-year, on average, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.XTRA:RDC Earnings Per Share Growth February 16th 2025
Given this is a high-level overview, we won’t go into details of Redcare Pharmacy's upcoming projects, though, keep in mind that by and large a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.
Before we wrap up, there’s one issue worth mentioning. Redcare Pharmacy currently has a relatively high level of debt. Generally, the rule of thumb is debt shouldn’t exceed 40% of your equity, which in Redcare Pharmacy's case is 46%. Note that a higher debt obligation increases the risk in investing in the loss-making company.
Next Steps:
There are too many aspects of Redcare Pharmacy to cover in one brief article, but the key fundamentals for the company can all be found in one place – Redcare Pharmacy's company page on Simply Wall St. We've also compiled a list of key aspects you should further research:
Valuation: What is Redcare Pharmacy worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Redcare Pharmacy is currently mispriced by the market. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Redcare Pharmacy’s board and the CEO’s background. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments |
| 26.01.25 06:01:35 |
Redcare Pharmacy Independent Deputy Chairman of Supervisory Board Acquires 29% More Stock |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Potential Redcare Pharmacy NV (ETR:RDC) shareholders may wish to note that the Independent Deputy Chairman of Supervisory Board, Frank Kohler, recently bought €238k worth of stock, paying €119 for each share. That's a very decent purchase to our minds and it grew their holding by a solid 29%.
Check out our latest analysis for Redcare Pharmacy
Redcare Pharmacy Insider Transactions Over The Last Year
Notably, that recent purchase by Frank Kohler is the biggest insider purchase of Redcare Pharmacy shares that we've seen in the last year. So it's clear an insider wanted to buy, at around the current price, which is €126. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. The good news for Redcare Pharmacy share holders is that an insider was buying at near the current price. Frank Kohler was the only individual insider to buy shares in the last twelve months.
Frank Kohler bought 4.90k shares over the last 12 months at an average price of €118. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!XTRA:RDC Insider Trading Volume January 26th 2025
Redcare Pharmacy is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this freelist of growing companies with recent insider purchasing, could be just the ticket.
Does Redcare Pharmacy Boast High Insider Ownership?
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Redcare Pharmacy insiders own about €400m worth of shares (which is 16% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
So What Do The Redcare Pharmacy Insider Transactions Indicate?
It is good to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Redcare Pharmacy. Nice! If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this freereport showing analyst forecasts for its future.
Story Continues
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this freelist of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments |
